(Incorporated in Delaware)

We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. We have built our Generate Platform to be a tight and fully-integrated loop (design–build–test–learn) to create proprietary, therapeutically relevant data and differentiated molecular solutions for the biological challenges we aim to address. In addressing these challenges, the Generate Platform can engineer solutions against therapeutic targets by either starting from existing reference proteins or suggesting completely novel ones without a reference starting point, also known as de novo design.

The Generate Platform’s therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing. The most advanced (of these engineered proteins) is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody. We are enrolling patients in pivotal Phase 3 clinical trials of GB-0895 dfor severe asthma. The first patient was dosed in one of the Phase 3 clinical trials on January 26, 2026.

We also expect to advance two additional computationally generated oncology product candidates into Phase 1 clinical trials in 2026.

Note: Net loss and revenue are for the year that ended Dec. 31, 2025.

(Note: Generate Biomedicines filed its S-1 for its IPO on Feb. 4, 2026, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)